Other purchases in the quarter include ICON plc (ICLR, Financial), which is a CRO (Contract Research Organization) providing outsourced drug research to the pharmaceutical industry. We observed from our investment in Covance that the industry is turning, so we purchased a stake in ICON to increase the Fund's exposure to the trend.
From Baron Funds’ first quarter 2013 commentary.
From Baron Funds’ first quarter 2013 commentary.